

A STRONG AND RAPID IMMUNOSUPPRESSION BY EXTRACELLULAR ROS- CLEAVING ENZYMES (GSH-PEROXIDASE, CATALASE, MnSOD, CuZnSOD) GIVES EVIDENCE FOR A PERMANENT, O_2^- AND O_2^{2-} -MAINTAINED INTERCELLULAR CROSS TALK, EVEN IN THE RESTING STATE

ROS- CLEAVING ENZYMES AS NOVEL IMMUNOSUPPRESSANTS AND HO_2 AND H_2O_2 AS WELL AS NH_3 AND POLYAMINES AS NOVEL "SECOND MESSENGERS"

Leskovaar, P., Dickelhuber, A., Schmidmaier, R., Abdalla, K., Graw, M.

Immunol. Biochem. Res. Lab., Urol. Dept., School of Medicine, University (TU) Munich

Some observations supporting the novel hypothesis: (I) Both H_2O_2 -cleaving enzymes GSH- peroxidase and catalase strongly suppress the activity of (a) resting (b) alloactivated, and (c) lectin-activated PBMCs. MnSOD and Cu/ ZnSOD also significantly inhibit PBMC-activity. The dependence of cell activity on the extracellular HO_2 and H_2O_2 even in resting cells gives evidence of a permanent cell cross-talk via ROS and allows the APCs (macrophages) to organize and coordinate the immune response (a) through a direct ROI secretion or (b) via post-modulation of secreted ROI by enzymes (catalase, GSH-POD, SOD). The activation of PBLs by HO_2 and H_2O_2 , generated by xanthine oxidase (XOD) was so strong that it worked even in pure PBS, containing only Na and K ions. (II) We consider NH_3 as a novel „second messenger“ which promotes proliferation (a) per se or (b) by synergizing with HO_2 (and H_2O_2). The mitogenic mechanism is based on pH increase ($H^+ + NH_3 = NH_4^+$). NH_3 can be released by L-glutaminase or L-asparaginase and sequestered by L-glutamine (or asparagine) synthase. Since all oncogenes and growth factors increase pH_i by 0.2-0.3 pH units, and as NH_3 per se induces cell division, we consider HO_2 and NH_3 as late downstream mediator molecules of cell proliferation. Moreover, polyamines (putrescine), formed by proliferation-associated ornithine decarboxylase, contribute to the pH_i increase. The cytosolic increase of both pH_i and Ca_i suggest the mitochondrial Ca²⁺ effluxer and bear with the ROS generation.

ESTABLISHMENT OF A STABLE MIXED ALLOGENEIC CHIMERISM BY THE SUCCESSIVE INJECTION OF A 1:1 MIXTURE OF MATURE, LIFESPAN-PREPROGRAMMED DONOR PLUS RECIPIENT T CELLS OR PBMCs, FOLLOWED BY A 1:1 MIXTURE OF IMMATURE, NON-DNA-PREMANIPULATED BONE MARROW OR STEM CELLS OF THE SAME DONOR : HOST ORIGIN

Leskovaar, P., Schmidmaier, R.

Immunol. Biochem. Res. Lab., Urol. Dept., School of Medicine, University (TU) Munich

The establishment of a stable mixed allogeneic chimerism (MACH) could be considered as one of the most urgent problems in adoptive immunotherapy.

One of the clinical situations where MACH plays a central role is the DLI treatment of relapsed bone marrow recipients; here, a preestablished MACH seems to modulate the GvM-accompanying GvHD towards a less aggressive form which may be restricted to the lymphohematologic system.

Since a prematurely established MACH coinduces tolerance against tumor cells, we consider an early MACH-induction rather as a contraproductive. GvM downregulating process and propose a changed clinical protocol, consisting of a transient fully allogeneic chimerism as the first step and MACH as the second step. In this way, the strong GvM effect, eradicating the MRD (minimal residual disease), is followed by a stable MACH which is able to prevent adverse side-effects, the GvHD (in BMT and HSCT) and the IIVGR (in organ transplantation), respectively.

A further important clinical indication for a stable MACH are bone marrow-correctable immunodeficiencies and (other) genetic diseases. Here, a lifelong coexistence of donor and host cells, i.e. a permanent donor : host tolerance is necessary to provide the patient with donor-derived immunocompetent cells and – in the case of diverse BMT treatable genetic diseases – with the gene defect-correcting (proficient) cells of a healthy donor.

OUR NOVEL APPROACHES (A) IN THE PREVENTION OF THE ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE (GvHD) AND – EVEN MORE IMPORTANT – (B) IN THE ERADICATION OF PRE-ESTABLISHED GvHD COULD HELP TO INTRODUCE CLINICALLY A VARIETY OF ADOPTIVE IMMUNOTHERAPIES.

Leskovaar, P., Schmidmaier, R.

Immunol. Biochem. Res. Lab., Urol. Dept., School of Medicine, University (TU) Munich

The most important implications of our animal experiments are as follows:

(a) The replacement of untreated donor splenocytes by DNA-premanipulated, lifespan-predetermined MIS ("MIS-BM/SC") effectors completely prevented GvHD and resulted in a dramatic improvement of the long-term survival rate (100% vs. 0%) both in the semi-syngeneic and fully allogeneic system.

(b) The eradication of the established GvHD is based on a radical elimination of alloreactive Tc cells of donor (donor I) origin through a combined treatment by chemo(radio)therapy, T(Tc)-depleting antibodies and the in vitro premanipulated, donor I-specific alloaggressive cytotoxic T cells of a further donor II, the so called 3rd party MIS-effectors ("MIS-GvH" effectors). The preconditioning of the patient suffering of GvHD can be carried out under non-ablative ("immunoablative") or myeloablative conditions. The efficiency of the "MIS-GvH" effectors can further be potentiated by the in vitro or in vivo prealloimmunization of donor II by donor I (whose T cells had induced the GvHD). An additional potentiation of the "MIS-GvH" effectors can be achieved by the vaccination of the donor II with hybrid cells, formed by the fusion of MHC II-positive cells (e.g. DC, B cells or macrophages of donor I with the APCs of donor II). An additional positive effect can be expected from the vaccination of the patient with a 2nd class of vaccines, based on cell hybrids of GvHD-inducing T cells with autologous (i.e. patient's) or allogeneic (donor I or II) HLA class II-positive (e.g. accessory) cells. Both types of the anti-GvHD vaccine are recommended especially in the case of the advanced or refractory GvHD.

TWO IMPORTANT IMPROVEMENTS OF THE CONVENTIONAL BMT AND HSCT: (A) THE ROUTINE USE OF A 1:1 MIXTURE OF D- AND R- DERIVED BMCs (OR HSCTs) PRECEDED BY THE 1:1 MIXTURE OF D- AND R- DERIVED MIS EFFECTORS, AND (B) THE ROUTINE USE OF HAPLOIDENTICAL MIS EFFECTORS, COMBINED WITH BMT OR HSCT

Leskovaar, P., Schmidmaier, R.

Immunol. Biochem. Res. Lab., Urol. Dept., School of Medicine, University (TU) Munich

The conventional allogeneic bone marrow and stem cell transplantation has the disadvantage that donor-type immunocytes continue to represent a kind of "foreign body". This results both in an impaired T cell : APC cooperation and in an affected recognition of tumor and viral structures on patient's own cells. Fine differences between tumor and normal cells can be recognized only if MHC I (and II) on tumor cells, APCs and thymic epithelial cells (responsible for MHC-restriction of T cells) are identical. In recipients of allogeneic bone marrow or stem cell grafts, the MHC-restriction of host thymus-educated T cells is different from the MHC structure on donor-derived accessory cells, so that the T cell : APC-cooperation is impaired. For this reason, we propose two improvements of existing techniques: (a) A routine use of a 1:1 mixture of donor plus recipient DNA-premanipulated mature T cells (or PBMCs), followed by the 1:1 mixture of the corresponding non-premanipulated immature bone marrow or stem cells. In this way, an optimized T cell : APC-cooperation can be restored, primarily due to the presence of the host-type APCs which are critical for the patient's immunocompetence against (retro)viral infections and malignancies. (b) The second improvement is the routine use of in vitro premanipulated MIS/MIT effectors, derived from haploidentical siblings, mimicking the above mentioned highly successful semi-allogeneic system (94,6% long-term survivors at a single treatment and a 100% long-term survival rate at a repeated treatment). Again, the central point is the appearance of common haplotype on the surface of the donor, the recipient and the transformed (or virally infected) target cells.